Preview

User

Not a user? Register with this site Forgot your password?

Systemic Hypertension

Advanced search

Combined antihypertensive therapy in the light of modern recommendations: strategy of one tablet

https://doi.org/10.26442/2075082X.2018.4.180110

Abstract

The review focuses on the main strategies of antihypertensive therapy set out in the 2018 ESC/ESH recommendations. The basis of antihypertensive therapy consists of five main classes of antihypertensive drugs, which should form the basis of the combined drug antihypertensive therapy in most patients. The single pill strategy is to take advantage of fixed combinations as a starting antihypertensive therapy for most patients. Among the fixed combinations, the combination of an ACE inhibitor with a diuretic (Noliprel®) remains one of the most preferred for antihypertensive therapy, since In addition to its antihypertensive potential, it has the ability to prevent renal, coronary complications and cerebrovascular events, to influence the progression of atherosclerosis, the occurrence of new cases of diabetes and to achieve a statistically significant reduction in total mortality

About the Author

T. E. Morozova
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation


References

1. Клинические рекомендации «Диагностика и лечение артериальной гипертонии», 2013. http://www.cardioweb.ru/klinicheskie-rekomendatsii

2. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 13 (4): 4-14.

3. Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. https://doi.org/10.1093/eurheartj/ehy339

4. Mancia G et al. ESH/ESC Guidelines for themanagement of arterial hypertension. J Hypertens 2013; 31: 1281-357.

5. Wald D.S et al. Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. Am J Med 2009; 122 (3): 290.

6. Национальные рекомендации Российского научного медицинского общества терапевтов по количественной оценке приверженности к лечению. М., 2017. https://www.rnmot.ru/public/uploads/RNMOT/clinical/2017.pdf

7. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. The Cochrane Collaboration: John Wiley and Sons, Ltd. Cochrane Database System Rev 2006; 4.

8. Sewitch M.J, Leffondre K, Dobkin P.L. Clustering patients according to health perceptions: relationhips to psychosocial characteristics and medication nonadherence. J Psychosom Res 2004; 56: 323-32.

9. Леонова М.В., Белоусов Д.Ю., Штейнберг Л.Л.; аналитическая группа исследования ПИФАГОР. Анализ врачебной практики проведения антигипертензивной терапии в России (по данным исследования ПИФАГОР III). Фарматека. 2009; 2: 98-103.

10. The PROGRESS Collaborative Group. Randomised trial of aperindopril-based blood-pressure-lowering among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.

11. Beckett N.S, Peters R, Fletcher A.E et al.; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008; 358: 1887-98.

12. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-40.

13. De Galan B.E, Perkovic V, Ninomiya T et al. On behalf of the ADVANCE Collaborativе Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrology. Еpub. 18 February 2009. DOI: 10.1681/ASN.2008070667.9.20

14. Ruilope L.M, Mancia G, Chalmers J. Does use of antihypertensive treatment to reduce albuminuria translate into effective benefits on outcome and mortality? A reappraisal of studies with renal endpoints in diabetes. J Hypertens. V. 28. DOI: 10.1097/01.hjh.0000379031.35224.c0

15. Zoungas S et al. NEJM, 2014 September 19. DOI: 10.1056/NEJMoa1407963

16. Глезер М.Г., Авакян А.А. Эффективность и безопасность терапии полнодозовой комбинацией периндоприла А/индапамида (10/2,5 мг) у пациентов с артериальной гипертонией. Кардиоваск. терапия и профилактика. 2012; 5: 4-11.

17. Карпов Ю.А. Программа ФОРТИССИМО: преимущества фиксированной полнодозовой комбинации периндоприла аргинина и индапамида в лечении плохо контролируемой артериальной гипертонии от имени участников программы ФОРТИССИМО. Кардиология. 2013; 3: 37-43.


Review

For citations:

Morozova T.E. Combined antihypertensive therapy in the light of modern recommendations: strategy of one tablet. Systemic Hypertension. 2018;15(4):92-96. https://doi.org/10.26442/2075082X.2018.4.180110

Views: 202


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)

OOO InterMedservice
Address: 121069, Russia, Moscow, Stolovy Lane, 6
Tel.: +7 (985) 763-98-00
e-mail: og@intermed.services

 

The media outlet is registered with the Federal Service for Supervision of Communications, Information Technology, and Mass Media (Roskomnadzor). Registration number and date of the decision on media registration: series EL No. FS 77 - 83918 dated 12.09.2022.

 

16+

Processing of personal data
supported by NEICON (Elpub lab)